Extracorporeal Photopheresis as a Possible Therapeutic Approach to Adults With Severe and Critical COVID-19

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

August 6, 2024

Study Completion Date

August 6, 2024

Conditions
COVID-19
Interventions
PROCEDURE

Extracorporeal photopheresis

ECP is initiated on study inclusion day by Therakos Cellex system, according to manufacturers' instructions. Each patient receives two ECP cycles for 2 weeks, each consisting of two sessions on consecutive days per week (alltogether four sessions), through a peripheral or central venous route. Cycles 1 and 2 are separated by 5 consecutive days. One ECP session takes \~3 hours, and is separated into 4 phases. On priming, the system performes a series of calibrations to ensure proper operation. During collection, 1500 ml of whole blood is processed to collect a concentrated buffy coat containing white blood cells, while other cells and plasma are reinfused. During the photoactive phase, a prescribed dose of 8-methoxypsoralen is added to the buffy coat, which is then circulated through ultraviolet-A photoactivation. During reinfusion phase, treated cells are automatically reinfused to the patient.

Trial Locations (1)

1097

South Pest Central Hospital, National Institute of Haematology and Infectious Diseases, Budapest

All Listed Sponsors
lead

Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases

OTHER

NCT05882331 - Extracorporeal Photopheresis as a Possible Therapeutic Approach to Adults With Severe and Critical COVID-19 | Biotech Hunter | Biotech Hunter